private:kiromic
|
3341795
|
May 29th, 2019 12:00AM
|
Kiromic
|
772
|
15.00
|
Open
|
Biotechnology
|
May 29th, 2019 09:01AM
|
May 29th, 2019 09:01AM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
Open
|
Cancer Research, Tumor Immunology, Cell Culture, Biopharmaceutical, Nanotechnology
|
Open
|
6104 45th Street, Suite D
|
Lubbock
|
TX
|
US
|
79407
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Mar 18th, 2018 12:00AM
|
Kiromic
|
743
|
17.00
|
Open
|
Biotechnology
|
Mar 18th, 2018 06:43PM
|
Mar 18th, 2018 06:43PM
|
|
Open
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 17th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 16th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 15th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 14th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 13th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 12th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 11th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|
private:kiromic
|
3341795
|
Feb 10th, 2018 12:00AM
|
Kiromic
|
740
|
18.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
|
|
|
|
|
|
|
|
|
|
Kiromic
|
|
Pharmaceuticals & Biotechnology
|